Adopting life-cycle HTA: a tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviews
We developed an open-source index economic evaluation to operationalize life-cycle HTA for a conditionally authorized tumor-agnostic therapy. Our findings outline key operational and methodological considerations necessary for the development of index economic models that support life-cycle HTA, offering insights into their potential integration into regular HTA and policy decision-making processes.
Authors
- Dean A. Regier (ORCID: https://orcid.org/0000-0001-8876-0511)
- Cheryl Ho (ORCID: https://orcid.org/0000-0002-5922-3984)
- Emanuel Krebs (ORCID: https://orcid.org/0000-0002-6590-8728)
- Gemma Cupples (ORCID: https://orcid.org/0000-0003-1353-1452)
- Deirdre Weymann
Institutions
- University of British Columbia (CA)
- Simon Fraser University (CA)
- Spinal Cord Injury BC (CA)
Publication Details
- Journal
- International Journal of Technology Assessment in Health Care
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1017/s0266462325100111
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca